Gilead Sciences (GILD) Net Cash Flow (2009 - 2026)

Gilead Sciences (GILD) has reported Net Cash Flow for 18 consecutive years, with -$4.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 55.11% year-over-year to -$4.4 billion; the trailing twelve-month figure through Jun 2026 stood at -$1.9 billion (down 184.45% YoY), and the FY2025 full-year result was -$2.5 billion, down 163.84% from the prior year.
• Net Cash Flow retreated to -$4.4 billion in Q2 2026 per GILD's latest filing, from $75.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $5.0 billion in Q4 2024 and bottomed at -$4.4 billion in Q2 2026.
• Historically, Net Cash Flow has averaged -$120.8 million across 5 years, with a median of $53.5 million in 2022.
• The widest YoY moves for Net Cash Flow: up 31614.29% in 2024, down 356.63% in 2024.
• Over 5 years, Net Cash Flow stood at $638.0 million in 2022, then tumbled by 46.24% to $343.0 million in 2023, then surged by 1360.64% to $5.0 billion in 2024, then plunged by 95.43% to $229.0 million in 2025, then slumped by 2034.5% to -$4.4 billion in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$4.4 billion, $75.0 million, and $229.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.